Abstract | BACKGROUND: Pediatric patients have a better survival rate for lymphoid malignancies than adolescents and young adult patients (AYA) and current evidence suggests that asparaginase plays a role in improved response to treatment. This study aimed to evaluate if increasing age as a continuous variable demonstrated increasing toxicities to PEG-asparaginase (PEG-ASP) for those patients treated at a tertiary care pediatric hospital. METHODS: A retrospective chart review from 2007 to 2017 was conducted in the pediatric population at the Children's Hospital of Eastern Ontario (CHEO). Patients having received PEG-ASP were included. Event incidence and risk related to age at diagnosis were assessed through parameter estimates and Wald chi-square analysis. RESULTS: CONCLUSION:
Allergic reaction and pancreatitis following administration of PEG-ASP have a higher risk of occurrence as age of diagnosis increases up to 18 years of age. This includes the lower limit of traditionally defined AYA population of 15-39 and warrants precaution as PEG-ASP is included in older populations treatment regimens at pediatric centers.
|
Authors | Lesleigh Abbott, Maia Claveau, Ken Tang, Jameason Cameron, Genevieve Goulet |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 110
Issue 1
Pg. 32-39
(Jan 2023)
ISSN: 1600-0609 [Electronic] England |
PMID | 36151599
(Publication Type: Journal Article)
|
Copyright | © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antineoplastic Agents
- Asparaginase
- pegaspargase
- Polyethylene Glycols
|
Topics |
- Adolescent
- Child
- Humans
- Young Adult
- Antineoplastic Agents
(therapeutic use)
- Asparaginase
(adverse effects)
- Hypersensitivity
- Pancreatitis
(chemically induced, epidemiology)
- Polyethylene Glycols
(adverse effects)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, epidemiology)
- Retrospective Studies
- Tertiary Care Centers
|